Indivior Pharmaceuticals, Inc.(INDV)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Indivior Pharmaceuticals, Inc. (INDV) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INDV at 58.5/100 on a 32-signal composite quality model, placing it at rank #1,006 of 2,961 stocks — the top half of the AI-ranked universe. INDV scores in the top quartile across balance sheet strength (97.9), profitability (89.9), institutional flow (81.4). Areas of concern include free cash flow (17.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Indivior Pharmaceuticals, Inc. reports quarterly revenue of $343.0M, net income of $122.0M, free cash flow of $222.0M. Top institutional holders of INDV by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, OAKTREE CAPITAL MANAGEMENT, based on the most recent SEC filings. INDV trades on the Nasdaq exchange and files with the SEC under CIK 1625297. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INDV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Indivior Pharmaceuticals, Inc. directly from SEC EDGAR.
AI Quality Score
58.5/100
AI Rank
#1,006
Revenue
$343.0M
Net Income
$122.0M
Free Cash Flow
$222.0M
INDV key financials by period
Indivior Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$1.2B
$210.0M
21.1%
FY 2024
10-K
$1.2B
$7.0M
3.2%
FY 2023
10-K
$1.1B
$-126.0M
-13.9%
FY 2022
10-K
$901.0M
$-44.0M
-9.0%
Institutions holding INDV
Institutional investors reporting a position in Indivior Pharmaceuticals, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-03 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net revenue grew 14% YoY to $343M on 22% SUBLOCADE growth in the US, while gross margin expanded to 85% even as the company discloses a pending all-stock merger with Supernus.
Biggest Revenue Drivers
Total U.S.$300M+17% YoY
Growth primarily driven by sales of SUBLOCADE in the U.S.
Rest of World$43M-7% YoY
Reflects exit from certain non-U.S. markets; company expects this trend to continue
Biggest Revenue Drivers
Total revenue: $343M+14% YoY
Total U.S.$300M+17% YoY
Growth primarily driven by sales of SUBLOCADE in the U.S.
Within Total U.S.
SUBLOCADE$238M+22% YoY
Driven by dispense unit volume growth (up 18%), gross-to-net benefits and favorable price mix
Sublingual & other (Film/other)$57M+10% YoY
Benefited from favorable Film gross-to-net adjustments, offset by decline in U.S. Film category share
PERSERIS$5M-35% YoY
Rest of World$43M-7% YoY
Reflects exit from certain non-U.S. markets; company expects this trend to continue
Largest Expense Items
Selling, general and administrative$122M-23% YoY
Decrease primarily driven by headcount reductions and cost savings related to corporate initiatives
Cost of sales$50M-3% YoY
Decrease attributable to a prior-year $10M SUBLOCADE inventory write-down, partly offset by ~$2M of inventory provisions tied to market exit activities
Research and development$12M-42% YoY
Reflects reduced R&D activity following decisions to cease Phase 3 development of INDV-6001 and not advance INDV-2000 internally
Margins: Gross margin rose to 85% from 83% a year ago, driven by SUBLOCADE volume growth and lower cost of sales, including a prior-year inventory write-down that did not recur.
Watch Items from the Filing
SUBLOCADE alone accounted for 74% of net revenue in Q2 2026, up from 69% a year earlier, deepening reliance on a single product.
Company entered an Agreement and Plan of Merger with Supernus on August 1, 2026 (all-stock merger of equals); a termination fee of $174M is payable by Indivior in certain circumstances.
Company ceased Phase 3 development of INDV-6001 and decided not to advance INDV-2000 internally, and states it is 'not currently pursuing any pipeline activities.'
Accrued litigation settlement expenses of $56M remain for opioid litigation, and the Dental MDL now covers approximately 1,967 cases naming ~26,307 plaintiffs.
Rest of World revenue declined 7% YoY to $43M due to exits from certain non-U.S. markets, a trend management expects to continue.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
